1635-

OCI 20 2003 PTO

and 5		Pate	Approved for erat and Trademark Office		igh xx/xx/xx, (OMB 06	
008//PTO Rev. 10/95	U.S. Department of Patent and Trader		Application Number	10/008	10/008,789		
			Filing Date	Noven	November 8, 2001		
TRANS	MITTAL FOR	.M	First Named Inventor	C. Fra	C. Frank Bennett et al.		
	orrespondence during pe iled application)	endency of	Group Art Unit Number	1635	1635		
			Examiner Name	Terra	Terra C. Gibbs		
Total Number of Pag	es in This Submission	5**	Attorney Docket Number	r 23546	- 07724 (RTS	3-0333)	
	ENCL	OSURES	(check all that ap	oly)			,
Return Receipt Response to Not Assignment & F Declaration Power of Attorn Application Data Information Disc Copie Request for Cool Request for Cool Amendment/Ret After Status Request Revocation and	otice to File Missing Part Recordation Cover Sheet ey a Sheet closure Statement & PTO es of IDS Cited Reference rrected Filing Receipt rrection of Recorded Ass esponse: [] Page(s)	t O-1449 ces signment	Appeal Comm Interferences Appeal Comm (Appeal Notice Certified Copy After Allowand	Draftspers g(s): et(s) of Figure unication to unication to e, Brief, Re of Priority	ure(s) [] o Board of Ap o Group eply Brief) Document(s)		nd
	SIGNAT	TURE OF	ATTORNEY OR AG	ENT			
Signature:	from 1	Howl					
Attorney/Reg. No.: Susan T. Hubl, Ph.D., Reg. No. 47,668 Dated: October 14,2003							, 2003
CERTIFICATE OF MAILING I hereby certify that this correspondence, including the enclosures identified above, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Non Fee Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.							
Signature:	Swam 1	Hw					
Typed or Printed Nar	ne: Susan T Huhl	Ph D Pater	nt Agent	Dated:	October	TU	2003

23546/07724/SF/5108251.1

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Submitted 10/14/03
Sheet 1 of

Complete if Known				
Application No.	10/008,789			
Filing Date	November 8, 2001			
First Named Inventor	C. Frank Bennett et al.			
Art Unit	1635			
Examiner Name	Terra C. Gibbs			
Attorney Docket Number	23546-07724 (RTS-0333)			

U.S. PATENT DOCUMENTS						
		Document No.				
Examiner Initials*	Cite No.1	Number – Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
	A1	US-5,801,154	08/06/1997	Baracchini		
	A2	US-				
	A3	US-				
	A4	US-				

	FOREIGN PATENT DOCUMENTS						
Foreign Patent Document							
Examiner Initials*	Cite No.1	Country Code ³ – Number ⁴ Kind Code ⁵ (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶		
	B1						
	B2						

	•	OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
	C1	Branch A. A Good Antisense Molecule is Hard to Find. TIBS, Vol. 23, pp 45-50, (Feb. 1998).					
	C2,	Fritz et al. Cationic Polystyrene Nanoparticles: Preparation and Characterization of a Model Drug Carrier System for Antisense Oligonucleotides. Journal of Colloid and Interface Science, Vol. 195: 272-288 (1997).					
	C3 ,	Jen, et al. Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells, Vol. 18 (2000).					
	C3 `	Schneider et al. Forschungszentrum Karlsruhe, FZKA 6587, pp 1-139 (2001), see abstract.					
	C4	Search Report from PCT/US02/35479					
	C5						

23546/07724/SF/5108075.1

Examiner	Date		
Signature	Considered		•
		l	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CANTS:

C. Frank Bennett et al.

APPLICATION NO.:

10/008,789

FILING DATE:

November 8, 2001

TITLE:

ANTISENSE MODULATION OF THYROID HORMONE RECEPTOR

INTERACTOR 6 EXPRESSION

EXAMINER:

1635

GROUP ART UNIT:

Terra C. Gibbs

ATTY. DKT. NO.:

23546-07724 (RTS-0333)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date shown below:

Dated: October

Musin 1 Hull Susan T. Hubl, Ph.D., Reg. No. 47,668

MAIL STOP NON-FEE AMENDMENT COMMISSIONER FOR PATENTS P. O. BOX 1450

ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner. Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Supple	mental	Inform	ation Disclosure Statement is being filed:				
		within three months of the filing date of the application, or date of entry into the national stage of an international application, or before the mailing					
			t office action on the merits, whichever event last occurred;				
			ailing of a first official action after the filing of a request for				
			camination (RCE) under 37 CFR § 1.114;				
\boxtimes			onths of the filing date of this national application or the date				
_			ne national stage in an international application, or after the				
			of the first official action on the merits, whichever event last				
			t before the mailing date of the first to occur of either: (1) a				
			ander 37 CFR §1.113; or (2) an action that otherwise closes				
			in the application, and:				
			ched hereto is the fee set forth under 37 CFR §1.17(p) for				
			mission of this Information Disclosure Statement under 37				
			2.§ 1.97(c); OR				
	\boxtimes	App	licant certifies pursuant to 37 CFR § 1.97(e) that:				
		\boxtimes	each item of information contained in this Information				
			Disclosure Statement was first cited in a communication				
			from a foreign patent office in a counterpart foreign				
			application not more than three months prior to the filing of				
			this Statement; OR				
			no item of information contained in this Information				
			Disclosure Statement was cited in a communication from a				
			foreign patent office in a counterpart foreign application				
			and, to the knowledge of the person signing this				
			certification after making reasonable inquiry, no item of				
			information contained in this Statement was known to any				
			individual designated under 37 CFR § 1.56(c) more than				
			three months prior to the filing of this Statement;				
	befor	e the p	ayment of the issue fee but after the mailing date of the first to				
	occui	of eith	ner: (1) a final action under 37 CFR § 1.113; or (2) an action				
	that c	therwi	se closes prosecution in the application, and:				
		Appl	icant certifies pursuant to 37 CFR. § 1.97(e) that:				
			each item of information contained in this Information				
			Disclosure Statement was cited in a communication from a				
			foreign patent office in a counterpart foreign application not				
			more than three months prior to the filing of this Statement;				
			or				

					Disclosiforeign jand, to the certification information individuals.	of information contained in this Information are Statement was cited in a communication from a patent office in a counterpart foreign application the knowledge of the person signing this ation after making reasonable inquiry, no item of tion contained in this Statement was known to any hal designated under 37 CFR § 1.56(c) more than conths prior to the filing of this Statement; AND
				attache	d hereto	is the fee set forth under 37 CFR §1.17(p) for
						his Information Disclosure Statement under 37
			- A 4l-		1.97(c);	
			contain accordi	ed in th	is Inforn	e issue fee. Applicant request that the information nation Disclosure Statement be placed in the file 1.97(i), although the information may not be TO.
		applica referen	ation No	. [APPI d therei	LICATION are her	S5 U.S.C. § 120, on the earlier filing date of prior ON NUMBER], filed on [FILING DATE], and the reby referenced, but are not required to be provided FR § 1.98(d).
		cited in and the § 1.560	n a comre commu(c) more	nunication than the	ion from n was no	ained in this Information Disclosure Statement was a a foreign patent office in a counterpart application, of received by any individual designated in 37 CFR a prior to the filing of this Information Disclosure
	\boxtimes		ant subr		no fee i	s required for the consideration of this Information
	Consid	leration	of the li	sted ref	erences	and favorable action are solicited.
						Respectfully submitted, C. FRANK BENNETT et al.
Dated:	Octobe	er (r Y	, 2003	- S H H S S N	Susan T. Hubl, Ph.D., Patent Application Reg. No. 47,668 Attorney for Applicants Fenwick & West LLP Silicon Valley Center 301 California Street Mountain View, CA 94041 Tel.: (415) 875-2316 Fax: (415) 281-1350